News

Novo Nordisk Issues Voluntary U.S. Recall of Wegovy Weight-Loss Injections

The recall affects four lots of Wegovy pens two with a 0.5 mg dose and two with a 1 mg dose, manufactured at Novo Nordisk’s facility in Bagsværd, Denmark. U.S. Food and Drug Administration (FDA) enforcement data classify the action as a Class II recall, meaning that while use of the product may lead to temporary or reversible medical effects, the likelihood of serious harm is low.

• By Newsdesk
• New Delhi
• Jan 09, 2026

News

Danish pharmaceutical giant Novo Nordisk has initiated a voluntary recall of select lots of its widely prescribed weight-loss medication Wegovy® in the United States after a quality inspection uncovered a potential issue with some prefilled injection pens, company and regulatory filings show. 

The recall affects four lots of Wegovy pens two with a 0.5 mg dose and two with a 1 mg dose, manufactured at Novo Nordisk’s facility in Bagsværd, Denmark. U.S. Food and Drug Administration (FDA) enforcement data classify the action as a Class II recall, meaning that while use of the product may lead to temporary or reversible medical effects, the likelihood of serious harm is low. 

According to Novo Nordisk, the potentially affected pens were identified during internal inspection and were never distributed to pharmacies or reached patients. Company statements emphasized that no injuries or adverse events have been linked to these specific lots, and any health risk is considered minimal. The recall was launched “out of an abundance of caution,” underscoring the company’s intent to maintain high standards of product safety and quality. 

Wegovy, which contains the active ingredient semaglutide, a GLP-1 receptor agonist has become one of Novo Nordisk’s top-selling drugs, used by patients for chronic weight management. It is marketed in more than 80 countries and has been a key growth driver for the company’s obesity treatment portfolio. 

The recall follows a period of intense competition and scrutiny in the U.S. weight-loss drug market, where rivals and generic versions of GLP-1 medications have pressured prices and market share. Analysts have noted that Novo Nordisk has faced challenges retaining its first-mover advantage against competitors. 

Novo Nordisk has pledged to cooperate with the FDA and stakeholders to ensure the recall process is handled swiftly and safely for pharmacies, distributors and patients. At this stage, health professionals and patients are not being advised to stop using other Wegovy products that were not part of the affected lots. 

As the recall unfolds, it highlights the ongoing balance pharmaceutical companies must strike between rapidly bringing innovative treatments to market and maintaining rigorous quality control a dynamic that has taken on added significance amid rising demand for obesity therapies.